In July 2023, Biogen said it would cut another 1,000 jobs on top of the nearly 1,000 positions globally it eliminated in 2022. CEO Christopher Viehbacher said in Monday’s announcement that ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Biogen has promoted its chief commercial officer, Michel Vounatsos, to become its new CEO, taking over from George Scangos. Vounatsos will take over the position from Scangos on 6 January.

although he will remain at the helm of Biogen until a new CEO is found to help oversee a revitalisation of the company. First-quarter revenues fell 6% to just over $2.5 billion as top earners ...

the company's CEO Chris Viehbacher told reporters on a press call Thursday. Biogen hopes Leqembi and other new products will drive growth as it reduces costs and grapples with plunging demand for ...

(Reuters) -Biogen raised its annual profit forecast and exceeded expectations for third-quarter profit on Wednesday, as new ...

President and CEO Christopher A ... a deeper understanding of Biogen's financial health and market position, InvestingPro offers 7 additional tips, providing a comprehensive view of the company's ...

Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast ... as part of a series of cost-saving measures, as CEO Christopher Viehbacher takes the lead to bring the ...

(Reuters) - Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting ... of a series of cost-saving measures, as CEO Christopher Viehbacher takes the lead to ...